Navigation Links
vivo in Medical Technology

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

... VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, ... array of in vitro readouts and advanced in vivo imaging technologies. The newly reported ... in vitro assays, microscopic readouts, and in vivo imaging methodologies, including Magnetic ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... Results from preclinical in vitro and in vivo studies of EP-100 in ovarian cancer cell lines ... The drug candidate was tested in vitro and in vivo for activity in LHRH receptor over-expressing ... that over-express LHRH receptors. In in vivo studies, the efficacy of EP-100 in comparison to ...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

... mesenchymal stem cells, which are processed ex vivo before reintroduction into the body, tend to ... cells in the bone marrow but reduced after ex vivo expansion) with the stromal-derived factor-1 ... that treatment of mesenchymal stem cells ex vivo with an Ad5IGF-1 biologic, such as Cardium's ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... SGI-1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic ... " Inhibiting PIM-1 is effective in vitro and in vivo against ALL: A novel mechanistic and potentially ... cell proliferation. In a clinically relevant in vivo model, NOD/SCID mice xenografted with human ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... Taligen Therapeutics Inc. today announced that in vivo data on several of the Company's ... for treating complement-mediated diseases In vivo studies in models for several complement-mediated ... injections. Growing pipeline Additional In vivo data were presented for CR2-Crry, a ...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

... and commercialization of fluorescence in vivo imaging technologies in a range of translational ... Agent platform was developed to provide in vivo readouts of some of the key protease activities ... customers worldwide to image disease-related in vivo protease profiles in pre-clinical research and ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... small molecule PIM kinase inhibitor with in vivo oral availability and activity in cell lines ... substrate for PIM, and may serve as a useful in vivo biomarker for future clinical trials. ... kinase inhibitor with in vivo oral ...

Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594

... Based on extensive in vitro and in vivo experiments, the Company believes it has ... URAT1 transporter-mediated uptake of uric acid ex vivo and increases uric acid excretion in animal ... on the URAT1-mediated uptake of uric acid ex vivo and is believed to be the active moiety ...

Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment

... treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 ... radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ...

Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220

... 12-16 in Phoenix, AZ. The results of the ex vivo response study along with the previously reported ... Phase 2 trials in the first half of 2008. Ex vivo Response Study data Interim data will be presented from an ex vivo response study designed to test the effect of ...

Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds

... in vitro screening and profiling, and in vivo animal models. This connection is critical as ... drug combination testing can be used to create in vivo tumor models to further assess efficacy using the ... adoption. Testing combinations in vitro and in vivo also ensures that new clinical compounds will not ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

... studies highlighting the in vitro activity and in vivo efficacy of its proprietary prodrugs in ... In the second study, entitled "In vivo Efficacy of a New Osteotropic Prodrug in a Rabbit ... prodrug (TT99000647) and its in vivo efficacy versus both gatifloxacin and rifabutin ...

Alfacell Provides Shareholder Update

... tumor growth inhibition from 37% to 73%. These in vitro and in vivo data, which are presently being prepared for publication emphasize the ... standard lung cancer chemotherapy regimen." Another independent study in vivo is underway that may confirm Dr. Pass' in vitro study. After much ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... 4-8 fold greater potency than linezolid in vitro and in vivo In vivo bactericidal activity Activity against all clinically important, ...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

... initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo regenerative effect. With FT1050, we are trying to affect stem cell ...

Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis

... with previous studies. -- Convenient dosing regimen: In an in vivo model of a chronic lung infection due to P. aeruginosa, MP-376 showed ... of its antibacterial effect. This was demonstrated in both in vitro and in vivo models and includes effects on both IL-6 and IL-8, cytokines which have ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... and Development, Westmont, Illinois -- Abstract #78: Poster -- In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase ... Takeda Pharmaceutical Company, Japan -- Abstract #51: Poster -- In vivo profiles of a novel compound, TAK-593, a highly potent and selective ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... A Novel Methionyl-tRNA Synthetase (MetRS) inhibitor -- F1-337: In vivo Efficacy of Rx100472, A Novel Methionyl-tRNA Synthetase (MetRS) ... of TR-701, a Novel Oxazolidinone Antibiotic -- F1-2065: In Vitro and In vivo Efficacy of TR-701 and TR-700 Versus the Linezolid- and ...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... production, multifaceted structural studies, lead identification, ex vivo and in vivo assays, cGMP manufacturing and regulatory capabilities which furnishes ...

Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

... its ability to advance siRNA products from discovery to the clinic. The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on ... to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a ...

Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions

... exceptional selectivity for anabolic activity in well-validated in vivo models. Radius expects to complete formal toxicology studies that will ... half of 2009. "We are highly encouraged by data on RAD140 from our in vivo models, which demonstrate RAD140's strong potential to build new bone and ...

Amikacin Inhale Shows Promising Results in Phase II Study

... usually responsible for Gram-negative pneumonia. High in vivo Amikacin Lung Deposition Correlates with in vitro Findings(5) This study ... Conference, May 19, 2008 (5) J. Fink, MS, et al. High in vivo Amikacin Lung Deposition after NKTR-061 dosing correlates with in ...

Caliper Life Sciences' Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center

... are actively studying tuberculosis infections in live animals using in vivo imaging technology. Caliper's IVIS Spectrum was specifically chosen for ... innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. ...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

... whether HA-dependent pericellular matrices produced in vitro and in vivo by hormone refractory prostate cancer cell line could be enzymatically ... Similar pericellular matrices containing HA were also assembled in vivo following inoculation of tumors around the bone in mice. -- ...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

... Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613). Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster ...

Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting

... demonstrates that MSI-1436 does not inhibit the dopamine transporter in vivo by directly measuring dopamine levels in the brain of rats after MSI-1436 ... suggested that MSI-1436 may interact with the dopamine transporter but in vivo behavioral tests in rats did not show DAT-inhibitory activity. Therefore, ...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... Neutrophils are immune cells implicated in COPD pathology and previous in vivo studies have suggested that TPI 1020 is more effective than budesonide at ... Neutrophils are immune cells implicated in COPD pathology and previous in vivo studies have suggested that TPI 1020 is more effective than budesonide at ...

PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy

... all 35 (100%) of the boys with samples evaluable in this analysis. The in vivo data indicated that, across all three dose levels of PTC124, 18/38 (47%) ... Children's Hospital of Philadelphia. "The combined in vitro and in vivo evidence of enhanced dystrophin expression and reduced muscle fragility ...

KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model

... were disclosed in a presentation titled, "Indications Discovery Using In vivo Pathways as Targets," at the second annual Drug Repositioning Summit ... Programs in Neurobiology KineMed's programs utilize proprietary in vivo technologies to indentify drug candidates that can modulate several key ...

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer

... growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks ... tumor types. While the mechanism of ERBITUX's anti- tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall ...

Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy

... two site blinded clinical study. The paper is entitled "The Impact of In vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma ... (2007), 0, 000-000, doi: 10.1038/sj.jid.5700993, "The Impact of In vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks ... tumor types. While the mechanism of ERBITUX's anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall ...

WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development

... development contract, remarked that, "With the success of the recent in vivo experiments, we are encouraged to begin 30-day animal implants, focusing ... President and CEO, commented, "The positive results of the initial in vivo implants highlight the potential benefits of WorldHeart's MagLev(TM) ...

Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

... Purchase Agreement (the "Agreement"), with an investor group comprised of vivo Ventures Fund VI L.P., vivo Ventures Fund VI Affiliates Fund, L.P., GCE Holdings LLC and certain ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs. Safe Harbor Statement This press release contains ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... barrier has generated much interest in exploring its potential activity in the treatment of patients with advanced brain tumors. In vitro and in vivo data presented at AACR 2009 by investigators from the National Cancer Institute demonstrated that single agent perifosine not only induced tumor ...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

... with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa , including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious ...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

... was based on work conducted by Access' collaborators at the Southern Research Institute. The paper is entitled "Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine" (thiarabine). A preprint of the paper is currently available for ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs. Safe Harbor Statement This press release contains forward-looking ...

Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

... lower respiratory tract infections, including Streptococcus pneumoniae and Haemophilus influenzae , (Poster P 1393). The second poster contains in vivo data demonstrating that, following oral administration, NXL103 was able to kill intracellular drug-resistant and non-drug-resistant strains of ...
Other Contents
(Date:7/14/2014)... German . , ... development. One classical example is the sequential and rhythmic ... that has been linked to the ticking of an ... now, this patterning process was thought to be determined ... periodically trigger new segment formation. However, this week in ...
(Date:7/14/2014)... MedNet Solutions , a global ... management systems, is pleased to announce that ... on software-as-a-service (SaaS) and Internet-based businesses, has made ... funding, representing the first major outside financing in ... the ongoing growth and development of both MedNet ...
(Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
(Date:7/14/2014)... July 14, 2014 The North America ... in North America with analysis and forecast of revenue. ... grow from around $273.1 million in 2013 to $490.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:7/14/2014)... Employers looking to lower their ... more benefit options must understand how purchasing benefits ... are the future of employee benefits. , Horizon ... BCBSNJ) is offering a free webinar, The Future ... Options, to demonstrate how HorizonSelect, its private online ...
(Date:7/14/2014)... Continuing a steady trend of growth in the ... of first-quarter success with Orange Regional Medical Center, Nexus ... by CEO and President Dr. Virginia Feldman – has ... members. Robert Poltenovage has joined the Nexus ... LPN and Angelica D’Amico have joined the Nexus Health ...
(Date:7/14/2014)... The European Lecithin Market report explains ... and projection of revenue. The Lecithin Market in Europe ... 2012 to $315.9 million by 2019, at a CAGR ... the TOC of the European Lecithin Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/14/2014)... use of antibiotics is still prevalent among terminal patients ... despite little evidence that the medications improve symptoms or ... effects. , The use of antibiotics is so engrained ... discharged from hospitals directly to a hospice program leave ... one fourth of them don,t have a documented infection ...
Breaking Medicine News(10 mins):Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 3Health News:Antibiotic use prevalent in hospice patients despite limited evidence of its value 2
Other TagsOther Tags